Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics, Safety, and Tolerability of 4-MUST in Healthy Volunteers
NCT07594977Phase 1Recruiting
- Sponsor
- Valenta Pharm
- Start
- Jan 2026
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of 4-MUST in chronic cholecystitis and biliary dyskinesia (3 arms), sponsored by Valenta Pharm. Primary endpoints: Maximum Observed Plasma Concentration, Time to Maximum Plasma Concentration and 7 more. Started Jan 2026; status: recruiting.
02
Drugs
4-MUST
03
Conditions
chronic cholecystitisbiliary dyskinesia
Beyond the preview
Go deeper on NCT07594977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07594977.